Live Breaking News & Updates on தேசிய பதக்கங்கள் ஆஃப் அறிவியல்

Stay updated with breaking news from தேசிய பதக்கங்கள் ஆஃப் அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Genius 100 Foundation & NY Festivals Advertising Awards Select IKEA "For A Safe Home" for Genius 100 Inspiration Award


Share This Article
G100 Judges: Jose M Sokoloff, James Caan, Obiageli Ezekwesili
Inaugural Genius 100 Inspiration Award was created to spotlight the global advertising campaign of 2020 that inspired the greatest social impact
We are so grateful to IKEA for creating and submitting this extremely arresting, powerful, gripping work - it is imperative that messages like this are spotlighted to inspire action and create impact”
Hilarie Viener, CEO, Genius 100 Foundation
NEW YORK, NEW YORK, UNITED STATES, July 19, 2021 /EINPresswire.com/ Genius 100 Foundation (G100) in partnership with New York Festivals International Advertising Awards
® are honored to announce IKEA’s “For A Safe Home” as the winner of the inaugural Genius 100 Inspiration Award. ....

Czech Republic , United States , United Kingdom , Hilarie Viener , Josem Sokoloff , Geoff Tabin , Obiageli Ezekwesili , Scott Rose , Sanduk Ruit , James Caan , Gift Of Sight Campaign , Supreme Court , Jose Miguel Sokoloff Mullenlowe Group Creative Council , Foundation Mission , York Festivals International Advertising , National Medals Of Science , Award Winner , New York Festivals International Advertising , Triad Advertising , Executive Director , Award Executive Jury , Jose Miguel Sokoloff , Mullenlowe Group Creative Council , Sight Campaign , Himalayan Cataract Project , Olympic Gold Medalists ,

The Vertebrate Genomes Project introduces a new era of genome sequencing


 E-Mail
The Vertebrate Genomes Project (VGP) today announces their flagship study and associated publications focused on genome assembly quality and standardization for the field of genomics. This study includes 16 diploid high-quality, near error-free, and near complete vertebrate reference genome assemblies for species across all taxa with backbones (i.e., mammals, amphibians, birds, reptiles, and fishes) from five years of piloting the first phase of the VGP project.
Nature, with companion papers simultaneously published in other scientific journals, the VGP details numerous technological improvements based on these 16 genome assemblies. In the flagship study, the VGP demonstrates the feasibility of setting and achieving high-quality reference genome quality metrics using their state-of-the-art automated approach of combining long-read and long-range chromosome scaffolding approaches with novel algorithms that put the pieces of the genome assembly puzzle together. ....

New York , United States , National Institutes Of Health , New Zealand , Rockefeller University , United Kingdom , San Diego Zoo , Chevy Chase , San Diego , Oxford Nanopore , Adam Phillippy , Richard Durbin , Pacific Biosciences , Erich Jarvis , Kerstin Howe , K Community Of Scientists , San Diego Zoo Wildlife Alliance , University Of Cambridge , Vertebrate Genome Laboratory , Max Planck Society Of Germany , Albert Lasker Medical Research , Max Planck Institute Of Molecular Cell Biology , National Center , Uc Santa Cruz Genomics Institute Genome Browser , Wellcome Sanger Institute , Howard Hughes Medical Institute Investigator ,

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutra


Search jobs
03-Feb-2021
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
NEW YORK (BUSINESS WIRE) Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.
Despite the increasing availability of the vaccines, there will continue to be patients who contract COVID-19 and will need treatment for their infection. This novel treatment is a combination of two mAbs directed at blocking the SARS-CoV-2 spike protein and neutralizing the virus. The mAbs have been engineered to be ....

Richardp Lifton , Bristol Myers Squibb , Rockefeller University Hospital , Bristol Myers Squibb Company , Exchange Commission , Rockefeller University , Albert Lasker Medical Research , National Medals Of Science , Senior Vice President , Bristol Myers , Myers Squibb , Juno Therapeutics , Lasker Medical Research Awards , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , ராக்ஃபெல்லர் பல்கலைக்கழகம் மருத்துவமனை , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் நிறுவனம் , பரிமாற்றம் தரகு , ராக்ஃபெல்லர் பல்கலைக்கழகம் , ஆல்பர்ட் லாஸ்கர் மருத்துவ ஆராய்ச்சி , தேசிய பதக்கங்கள் ஆஃப் அறிவியல் , மூத்தவர் துணை ப்ரெஸிடெஂட் , பிரிஸ்டல் மைஸ் ,